Singapore, March 31 -- Lunit, a South Korea-based provider of artificial intelligence (AI) for cancer diagnostics and precision oncology, and CellCarta, a Canada-based contract research organization (CRO) laboratory to the biopharmaceutical industry, have announced a strategic partnership to accelerate adoption of AI-enabled digital pathology workflows across translational research, clinical trials and companion diagnostic (CDx) programmes.

Published by HT Digital Content Services with permission from BioSpectrum Asia....